original ) (raw )Is there a pharmacodynamic need for the use of continuous versus intermittent infusion with ceftazidime against Pseudomonas aeruginosa? An in vitro pharmacodynamic model
María-José Giménez
Journal of Antimicrobial Chemotherapy, 2005
View PDFchevron_right
Comparative In Vitro and In Vivo Efficacies of Human Simulated Doses of Ceftazidime and Ceftazidime-Avibactam against Pseudomonas aeruginosa
Wright W Nichols
Antimicrobial Agents and Chemotherapy, 2012
View PDFchevron_right
Continuous versus Intermittent Infusions of Ceftazidime for Treating Exacerbation of Cystic Fibrosis
I. Sermet-gaudelus
Antimicrobial Agents and Chemotherapy, 2009
View PDFchevron_right
Use of ceftazidime in the therapy of serious infections, including those due to multiresistant organisms
B. Gordts
Antimicrobial Agents and Chemotherapy, 1983
View PDFchevron_right
Continuous infusion versus intermittent infusion of ceftazidime for the treatment of pneumonia caused by Pseudomonas aeruginosa
Leonardo Lorente
Critical Care, 2005
View PDFchevron_right
Ceftazidime in treatment of acute pulmonary exacerbations in patients with cystic fibrosis
R. Padoan
The Journal of Pediatrics, 1983
View PDFchevron_right
Clinical experience with ceftazidime/avibactam in patients with severe infections, including meningitis and lung abscesses, caused by extensively drug-resistant Pseudomonas aeruginosa
Roberto Luzzati
International journal of antimicrobial agents, 2016
View PDFchevron_right
Efficacies of Ceftazidime-Avibactam and Ceftazidime against Pseudomonas aeruginosa in a Murine Lung Infection Model
Wright W Nichols
Antimicrobial Agents and Chemotherapy, 2014
View PDFchevron_right
Ceftazidime and amikacin alone and in combination against Pseudomonas aeruginosa and Enterobacteriaceae
Dale Gerding
Diagnostic Microbiology and Infectious Disease, 1987
View PDFchevron_right
Lung deposition of continuous and intermittent intravenous ceftazidime in experimental Pseudomonas aeruginosa bronchopneumonia
Marc Tonnellier
Intensive Care Medicine, 2006
View PDFchevron_right
Serum bactericidal activity of ceftazidime and cefoperazone alone or in combination with amikacin against Pseudomonas aeruginosa and Klebsiella pneumoniae
Hjalmar Lagast
Antimicrobial Agents and Chemotherapy, 1983
View PDFchevron_right
Ceftazidime-Avibactam for the Treatment of Serious Gram-Negative Infections with Limited Treatment Options: A Systematic Literature Review
Alex Soriano
Infectious Diseases and Therapy, 2021
View PDFchevron_right
Continuous vs thrice-daily ceftazidime for elective intravenous antipseudomonal therapy in cystic fibrosis
Manfred Ballmann
Infection, 2009
View PDFchevron_right
Ceftazidime/avibactam activity tested against Gram-negative bacteria isolated from bloodstream, pneumonia, intra-abdominal and urinary tract infections in US medical centres (2012)
Helio Sader
Journal of Antimicrobial Chemotherapy, 2014
View PDFchevron_right
Avibactam confers susceptibility to a large proportion of ceftazidime-resistant Pseudomonas aeruginosa isolates recovered from cystic fibrosis patients
A. Vergison
The Journal of antimicrobial chemotherapy, 2015
View PDFchevron_right
Longitudinal analysis of the in vitro activity of ceftazidime-avibactam vs. Pseudomonas aeruginosa, 2012–2016
Elmano Ramalheira
Diagnostic Microbiology and Infectious Disease, 2019
View PDFchevron_right
Time–Kill Analysis of Ceftolozane/Tazobactam Efficacy Against Mucoid Pseudomonas aeruginosa Strains from Cystic Fibrosis Patients
Kayla Stover
Infectious Diseases and Therapy, 2017
View PDFchevron_right
Evaluation of in vitro activity of ceftolozane-tazobactam compared to other antimicrobial agents against Pseudomonas aeruginosa isolates from cystic fibrosis patients
ersilia fiscarelli
Diagnostic Microbiology and Infectious Disease, 2019
View PDFchevron_right
Optimizing ceftazidime pharmacodynamics in patients with acute exacerbation of severe chronic bronchitis
Tobias Welte
Journal of Antimicrobial Chemotherapy, 2003
View PDFchevron_right
Antibacterial Activity In Vitro and Regression Studies for Ceftazidime and Ceftriaxone
Niels Frimodt-møller
Acta Pathologica Microbiologica Scandinavica Series B: Microbiology, 2009
View PDFchevron_right
Suboptimal Concentrations of Ceftazidime/Avibactam (CAZ-AVI) May Select for CAZ-AVI Resistance in Extensively Drug-Resistant Pseudomonas aeruginosa: In Vivo and In Vitro Evidence
Nuria Campillo
Antibiotics
View PDFchevron_right
In-vitro Efficacy of Ceftazidime in Combinations with Meropenem, Piperacillin/Tazobactam, Amikacin and Ciprofloxacin against Extensively Drug-Resistant Pseudomonas aeruginosa
Aamir Jamal Gondal , Waqas Latif
Pakistan journal of zoology
View PDFchevron_right
A propensity score-matched analysis of the impact of minimum inhibitory concentration on mortality in patients with Pseudomonas aeruginosa bacteremia treated with cefepime or ceftazidime
Chris Gentry
Diagnostic Microbiology and Infectious Disease, 2017
View PDFchevron_right
Optimal exposures of ceftazidime predict the probability of microbiological and clinical outcome in the treatment of nosocomial pneumonia
Johan Mouton
Journal of Antimicrobial Chemotherapy, 2013
View PDFchevron_right
Ceftolozane/Tazobactam Therapy of Respiratory Infections due to Multidrug-Resistant Pseudomonas aeruginosa
Kerry Cleveland
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2015
View PDFchevron_right
Ceftolozane/tazobactam for the treatment of serious Pseudomonas aeruginosa infections: a multicentre nationwide clinical experience
Tiziana Tieghi
International Journal of Antimicrobial Agents, 2018
View PDFchevron_right
Clinical Experience with Ceftazidime-Avibactam for the Treatment of Infections due to Multidrug-Resistant Gram-Negative Bacteria Other than Carbapenem-Resistant Enterobacterales
Roberto Luzzati
Antibiotics, 2020
View PDFchevron_right
Comparison of clinical cure rates in adults with ventilator-associated pneumonia treated with intravenous ceftazidime administered by continuous or intermittent infusion: A retrospective, nonrandomized, open-label, historical chart review
Alejandro Jimenez
Clinical Therapeutics, 2007
View PDFchevron_right